Working… Menu

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01685892
Recruitment Status : Active, not recruiting
First Posted : September 14, 2012
Last Update Posted : November 19, 2019
AbbVie (prior sponsor, Abbott)
Information provided by (Responsible Party):
Genentech, Inc.